TuisAGIO • NASDAQ
add
Agios Pharmaceuticals Inc
Vorige sluiting
$33,42
Dagwisseling
$32,53 - $33,73
Jaarwisseling
$23,42 - $62,58
Markkapitalisasie
1,89 mjd USD
Gemiddelde volume
606,75 k
P/V-verhouding
2,90
Dividend-opbrengs
-
Primêre beurs
NASDAQ
Marknuus
Investopedia
1 uur gelede
S&P 500 Gains and Losses Today: Paychex Stock Drops; Nvidia, Supermicro Rise
0,00033%
9,40%
8,80%
4,33%
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Inkomste | 8,73 m | 6,56% |
Bedryfskoste | 41,53 m | 33,90% |
Netto inkomste | -89,29 m | -9,49% |
Netto winsgrens | -1,02 k | -2,75% |
Wins per aandeel | -1,55 | -6,90% |
EBITDA | -105,35 m | -16,12% |
Effektiewe belastingkoers | — | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 893,38 m | 49,40% |
Totale bates | 1,56 mjd | 83,06% |
Totale aanspreeklikheid | 88,99 m | -15,88% |
Totale ekwiteit | 1,47 mjd | — |
Uitstaande aandele | 57,92 m | — |
Prys om te bespreek | 1,32 | — |
Opbrengs op bates | -16,56% | — |
Opbrengs op kapitaal | -17,10% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | -89,29 m | -9,49% |
Kontant van bedrywe | -111,49 m | -11,64% |
Kontant van beleggings | 112,59 m | -9,61% |
Kontant van finansiering | 1,62 m | -72,39% |
Netto kontantverandering | 2,72 m | -91,11% |
Beskikbare kontantvloei | -87,33 m | -20,46% |
Meer oor
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013. Wikipedia
Gestig
2008
Webwerf
Werknemers
487
